Bottom line
Is FBIOX a good fund? The bottom line
FBIOX is a managed technology sector mutual fund from Fidelity.
Annual fees run 0.62% — about $62 a year on every $10,000 invested, cheaper than 67% of technology sector funds we track.
It returned +36.4% over one year, +3.5% a year over five years, +6.9% a year over ten (as of Apr 30, 2026, per its prospectus).
With $5.3 billion in net assets and 215 holdings, its largest position is Krystal Biotech Inc (10.6%) and the top 10 make up 46.4% of the portfolio.
What stands out
- Broadly diversified (215 holdings)
Updated Nov 19, 2026
What FBIOX invests in
Biotechnology Portfolio seeks capital appreciation.
Normally investing at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes , and companies that benefit significantly from scientific and technological advances in biotechnology. These companies may include, for example, companies engaged in the research, development, manufacturing, or marketing of products based in whole or in part on genetic analysis and genetic engineering. For purposes of the fund's policy to normally invest at least 80% of its assets in securities of companies principally engaged in the business activity or activities identified for the fund, Fidelity may consider a company to be principally engaged in the designated business activity or activities based on: (i) the level of a company's assets, income, sales, or profits that are…
From the fund's prospectus (filed Apr 24, 2026).
FBIOX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| FBIOX | +36.4% | +3.5% | +6.9% |
| Technology Sector median | +24.0% | +10.0% | +16.7% |
Source: Fund prospectus, as of Apr 30, 2026
What FBIOX costs
On a $10,000 investment, FBIOX's 0.62% expense ratio costs about $62 a year. The prospectus estimates $774 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.
FBIOX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Krystal Biotech Inc | 10.58% |
| 2 | Abbvie Inc | 9.22% |
| 3 | Amgen Inc | 6.53% |
| 4 | Gilead Sciences Inc | 4.82% |
| 5 | Fidelity Revere Street Trust | 3.35% |
| 6 | Alnylam Pharmaceuticals Inc | 2.93% |
| 7 | Praxis Precision Medicines Inc. | 2.47% |
| 8 | Insmed Inc | 2.25% |
| 9 | Argenx Se | 2.25% |
| 10 | Ascendis Pharma A/s | 2.04% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 46.4% of the fund. See all top 25 holdings and asset mix →